Clinical Trials Logo

Invasive Ductal Carcinoma clinical trials

View clinical trials related to Invasive Ductal Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04349111 Withdrawn - Clinical trials for Ductal Carcinoma In Situ

An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"

Start date: June 30, 2022
Phase: N/A
Study type: Interventional

The purpose of this trial is to assess the efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer. A comparison will be made to the current standard of care, whole breast irradiation (WBI), in women with early stage breast cancer.

NCT ID: NCT02365714 Terminated - Breast Cancer Clinical Trials

CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)

CK-SAPBI
Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study will prospectively evaluate the technical feasibility, acute toxicity, late effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) in early stage breast cancer. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects and cosmetic results.

NCT ID: NCT01796041 Completed - Clinical trials for Invasive Ductal Carcinoma

Intraoperative Imaging of Breast Cancer With Indocyanine Green

ICG
Start date: July 2011
Phase: Early Phase 1
Study type: Interventional

According to the World Health Organization, breast cancer is the most common cancer in women, and is responsible for 686,000 new cases every year. The WHO also posit that nearly 420,000 women perished from the disease in 2002. Surgery remains the best option for patients presenting with operable Stage I, II or III cancers. Breast conservation surgery has been shown to be as efficacious as mastectomy. About 60-70% of these women with operable breast cancer are breast conservation candidates. However, the need to achieve negative tumor margins often requires a second operation (re-excision) in up to 70% of the women having lumpectomy surgery. Currently, tumor margins assessment in the operating room is often assessed grossly by palpation. The ability to evaluate tumor margin using our proposed intraoperative imaging technique may provide the surgeon with an alternative, and hopefully, more sensitive method to assess tumor margins which may decrease re-excision and the morbidity associated with additional surgery, and, perhaps, lower the risk of local regional recurrence.

NCT ID: NCT01644669 Active, not recruiting - Clinical trials for Ductal Carcinoma in Situ

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Start date: May 8, 2012
Phase: N/A
Study type: Interventional

The purpose of this trial is to assess the safety and efficacy of the Xoft Axxent eBx System when used for single-fraction IORT in early stage breast cancer. Hypothesis: IORT using the Xoft Axxent eBx System is no worse (non-inferior) than whole breast irradiation (WBI) when used as stand-alone radiation treatment in breast conserving therapy in women with early stage breast cancer.

NCT ID: NCT01038258 Active, not recruiting - Clinical trials for Lobular Breast Carcinoma

Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy

PETBreast
Start date: July 2007
Phase: N/A
Study type: Interventional

A PET scan drop less than 20% in SUVs or below a certain absolute SUV value after the first course of neoadjuvant chemotherapy can predict pathological response, and could in the future lead to an early surgical intervention.